Agios (agios.com) is a biopharmaceutical company committed to applying our scientific leadership in cellular metabolism to transform the lives of patients with cancer and rare genetic diseases. We are growing rapidly with an active research and discovery pipeline across both therapeutic areas. Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.
Our lead rare genetic disease program, Mitapivat, is in Phase 3 clinical development for the treatment of pyruvate kinase (PK) deficiency with positive topline results announced in early December that the first of two registration-enabling trials met its primary endpoint. Mitapivat is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes. Mutations in PKR cause deficiencies in red blood cell glycolysis, which lead to a disease known as PK deficiency. PK deficiency is an inherited disease that causes lifelong hemolytic anemia as well as other serious complications. Activation of wild-type PKR has potential utility in other hemolytic anemias such as thalassemia and sickle cell disease; Agios is currently evaluating Mitapivat in both disease areas and expects to initiate pivotal trials this year.
The Hemolytic Anemia Specialist will report to a Regional Business Director, Rare Genetic Diseases, and will be a founding member of a new, best-in-class rare disease sales team. Each Hemolytic Anemia Specialist will be responsible for raising awareness of PKD across their respective geographies in anticipation of the initial US approval of Mitapivat for Pyruvate Kinase Deficiency (PKD).
We are seeking individuals with a demonstrated track record of success in launching rare diseases medicines and who are skilled at understanding the unique business drivers within their geography. The Hemolytic Anemia Specialists should possess a scrappy “start-up” mentality and values consistent with the patient and science focused Agios culture. They will be motivated by the opportunity to bring a rare disease commercialization mindset and to build their markets which will lay the foundation for the success of Mitapivat and Agios’ pipeline of transformative rare genetic disease treatments.
As a Hemolytic Anemia Specialist, you are the territory business owner with a focus on increasing HCPs awareness of Pyruvate Kinase Deficiency and PKD patient diagnoses across your geography
Develop an integrated launch plan for your geography reflecting deep analysis and clear prioritization
Collaborate with all field teams and marketing to ensure alignment on objectives, strategies, and communication
Develop relationships with key customers and continue to build knowledge of the hemolytic anemia marketplace
Collaborate with Regional Medical Affairs and Market Access colleagues to ensure seamless field coordination and customer/patient support
Upon launch, drive commercial team performance to get treatment to patients and deliver on revenue objectives while continuously assessing performance metrics and adjusting strategies and plans to achieve
Develop strong internal and external relationships to enable appropriate, compliant business partnerships
Ensure appropriate and compliant utilization of approved corporate, promotional and other resources to facilitate customer engagements
Represent Agios positively and professionally at company meetings and conferences, ensuring your activities are compliant with laws, regulations, policies and guidelines
Achieve or exceed sales forecasts and targets, within budget
Lead ad-hoc initiatives to support the business as requested
Bachelor’s degree required, Scientific degree a plus
Proven track record of success in Rare Disease sales; minimum 5 years’ experience in rare disease. Hematology sales experience preferred
Demonstrated understanding of the payer and clinical landscape, especially in specialty & rare diseases
Demonstrated business acumen and clinical knowledge expertise
Previous cross functional collaboration with internal stakeholders including: marketing, medical affairs, market access, patient services, and sales operations
Results-oriented with ability to thrive in a fast-paced, entrepreneurial environment
Ability to navigate ambiguity and drive results
Strong, resourceful, self-starter with an innovative mindset and ability to develop and execute new business solutions
Extraordinary commitment to customer experience and standards of excellence
Willingness to travel extensively across large geographies
Established relationships with Hematology HCPs within designated geography
Prior experience launching rare disease products
Experience leading regional and/or national initiatives
Current travel requirements are limited due to COVID. Both virtual or in-person meetings are facilitated as needed and appropriate. As travel opens back up and restrictions are lifted, travel requirement will be an average of 50-60% within the territory focusing on the major market areas.
About Agios Pharmaceuticals
Developing breakthrough medicines for patients with cancer and rare genetic diseases is incredibly important, and so challenging. It takes great science. But it also takes an environment where people care – about the work, about each other, and about patients.
At our core, we’re a biopharmaceutical company passionately committed to applying our leadership in the field of cellular metabolism to transform the lives of patients. We’re a science-driven, patient-focused organization developing transformative therapies across three major focus areas: hematologic malignancies, solid tumors and rare genetic diseases.
Patients are counting on us, and we’re driven by a sense of urgency to help. We challenge ourselves to think big and welcome different perspectives and backgrounds. And we deliver. We have two approved oncology precision medicines and multiple first-in-class investigational therapies in development. So far. Our research engine continues to yield new insights and potential therapeutic approaches, growing our differentiated portfolio of preclinical, clinical and commercial programs.
Through it all, we are propelled by our connections with one another and our shared goa...l of doing something extraordinary on behalf of those in need. Together, we can achieve the Other Side of Possible.